11.42
-0.56(-4.67%)
Currency In USD
| Previous Close | 11.98 |
| Open | 11.9 |
| Day High | 12.05 |
| Day Low | 11.22 |
| 52-Week High | 18.31 |
| 52-Week Low | 2.21 |
| Volume | 1.44M |
| Average Volume | 1.03M |
| Market Cap | 890.91M |
| PE | -3.04 |
| EPS | -3.76 |
| Moving Average 50 Days | 14.81 |
| Moving Average 200 Days | 11.26 |
| Change | -0.56 |
If you invested $1000 in Phathom Pharmaceuticals, Inc. (PHAT) since IPO date, it would be worth $464.23 as of February 21, 2026 at a share price of $11.42. Whereas If you bought $1000 worth of Phathom Pharmaceuticals, Inc. (PHAT) shares 5 years ago, it would be worth $249.62 as of February 21, 2026 at a share price of $11.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
Management to host conference call on Thursday, February 26, 2026, at 8:00 am ESTFLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializi
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that memb
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 08, 2026 3:33 AM GMT
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the prici